Gene Symbol: TCL1
Description: T cell leukemia/lymphoma 1A
Alias: TCL1, T-cell leukemia/lymphoma protein 1A, T-cell lymphoma-1, oncogene TCL-1, oncogene TCL1, protein p14 TCL1
Species: human
Products:     TCL1

Top Publications

  1. Hoyer K, Herling M, Bagrintseva K, Dawson D, French S, Renard M, et al. T cell leukemia-1 modulates TCR signal strength and IFN-gamma levels through phosphatidylinositol 3-kinase and protein kinase C pathway activation. J Immunol. 2005;175:864-73 pubmed
    A signaling role for T cell leukemia-1 (TCL1) during T cell development or in premalignant T cell expansions and mature T cell tumors is unknown...
  2. Noguchi M, Ropars V, Roumestand C, Suizu F. Proto-oncogene TCL1: more than just a coactivator for Akt. FASEB J. 2007;21:2273-84 pubmed
    ..Deregulation of this Akt signaling pathway underlies various human neoplastic diseases. Recently, the proto-oncogene TCL1 (T cell leukemia 1), with a previously unknown physiological function, was shown to interact with the Akt ..
  3. Despouy G, Joiner M, Le Toriellec E, Weil R, Stern M. The TCL1 oncoprotein inhibits activation-induced cell death by impairing PKCtheta and ERK pathways. Blood. 2007;110:4406-16 pubmed
    The TCL1/MTCP1 oncogenes were identified on the basis of their involvement in T-cell prolymphocytic leukemia (T-PLL)...
  4. Hoh F, Yang Y, Guignard L, Padilla A, Stern M, Lhoste J, et al. Crystal structure of p14TCL1, an oncogene product involved in T-cell prolymphocytic leukemia, reveals a novel beta-barrel topology. Structure. 1998;6:147-55 pubmed
    ..chromosome rearrangements characterized by the juxtaposition of the TCRA locus on chromosome 14q11 and either the TCL1 gene on 14q32.1 or the MTCP1 gene on Xq28...
  5. Laine J, Künstle G, Obata T, Sha M, Noguchi M. The protooncogene TCL1 is an Akt kinase coactivator. Mol Cell. 2000;6:395-407 pubmed
    ..1 or Xq28 regions. The regions encode a family of protooncogenes (TCL1, MTCP1, and TCL1b) of unknown function. In yeast two-hybrid screening, we found that TCL1 interacts with Akt...
  6. Fu T, Virgilio L, Narducci M, Facchiano A, Russo G, Croce C. Characterization and localization of the TCL-1 oncogene product. Cancer Res. 1994;54:6297-301 pubmed
    ..Thus, TCL-1 may represent a member of a novel family of genes involved in lymphoid proliferation and/or survival and in T cell malignancies. ..
  7. Pekarsky Y, Hallas C, Croce C. The role of TCL1 in human T-cell leukemia. Oncogene. 2001;20:5638-43 pubmed
    The TCL1 locus on human chromosome 14q32.1 is activated in T-cell leukemias by translocations and inversions that juxtapose it to regulatory elements of T-cell receptor genes...
  8. Pekarsky Y, Palamarchuk A, Maximov V, Efanov A, Nazaryan N, Santanam U, et al. Tcl1 functions as a transcriptional regulator and is directly involved in the pathogenesis of CLL. Proc Natl Acad Sci U S A. 2008;105:19643-8 pubmed publisher
    ..Deregulation of the T cell leukemia/lymphoma 1 (TCL1) oncogene in mouse B cells causes a CD5-positive leukemia similar to aggressive human B-CLLs...
  9. Ingle J, Schaid D, Goss P, Liu M, Mushiroda T, Chapman J, et al. Genome-wide associations and functional genomic studies of musculoskeletal adverse events in women receiving aromatase inhibitors. J Clin Oncol. 2010;28:4674-82 pubmed publisher
    ..These findings provide a focus for further research to identify patients at risk for MS-AEs and to explore the mechanisms for these adverse events. ..

More Information

Publications151 found, 100 shown here

  1. de Souza R, Kamat N. Three dimensional typological studies using scanning electron microscopy for characterization of Termitomyces pellets obtained from submerged growth conditions. Biotech Histochem. 2018;93:25-35 pubmed publisher
    ..striatus (TSTR), T. aurantiacus (TAUR), T. heimii (THE1, THE2), T. globulus (TGLO) and T. clypeatus (TCL1, TCL2, TCL3, TCL4, TCL5)...
  2. Reiff S, Mantel R, Smith L, Greene J, Muhowski E, Fabian C, et al. The BTK Inhibitor ARQ 531 Targets Ibrutinib-Resistant CLL and Richter Transformation. Cancer Discov. 2018;8:1300-1315 pubmed publisher
    ..i>In vivo, ARQ 531 was found to increase survival over ibrutinib in a murine Eμ-TCL1 engraftment model of CLL and a murine Eμ-MYC/TCL1 engraftment model resembling Richter transformation...
  3. Paparidis G, Akrivou M, Tsachouridou V, Shegani A, Vizirianakis I, Pirmettis I, et al. Synthesis and evaluation of 99mTc/Re-tricarbonyl complexes of the triphenylphosphonium cation for mitochondrial targeting. Nucl Med Biol. 2018;57:34-41 pubmed publisher
    ..Biodistribution of 99mTcL1 and 99mTcL2 were performed on SCID mice bearing U-87 MG tumors...
  4. Rosenquist R, Cortese D, Bhoi S, Mansouri L, Gunnarsson R. Prognostic markers and their clinical applicability in chronic lymphocytic leukemia: where do we stand?. Leuk Lymphoma. 2013;54:2351-64 pubmed publisher
    ..g. CD38, ZAP70, TCL1), the RNA (e.g. LPL, CLLU1, micro-RNAs) and the genomic (e.g. TP53, NOTCH1, SF3B1 and BIRC3 mutations) level...
  5. Lee S, Sakakibara S, Maruo S, Zhao B, Calderwood M, Holthaus A, et al. Epstein-Barr virus nuclear protein 3C domains necessary for lymphoblastoid cell growth: interaction with RBP-Jkappa regulates TCL1. J Virol. 2009;83:12368-77 pubmed publisher
    ..Takada, Proc. Natl. Acad. Sci. USA 103:19500-19505, 2006). We have confirmed that EBNA3C upregulates TCL1 and discovered that EBNA3C upregulates TCL1 through RBP-Jkappa, indicating a central role for EBNA3C interaction ..
  6. McKenna M, Noothi S, Alhakeem S, Oben K, Greene J, Mani R, et al. Novel role of prostate apoptosis response-4 tumor suppressor in B-cell chronic lymphocytic leukemia. Blood. 2018;: pubmed publisher
    ..We found that chronic lymphocytic leukemia (CLL) cells from human patients and from the Eµ-Tcl1 mice constitutively express Par-4 in greater amounts than normal B-1 or B-2 cells...
  7. Tominaga Wada R, Nukumizu Y, Sato S, Wada T. Control of plant trichome and root-hair development by a tomato (Solanum lycopersicum) R3 MYB transcription factor. PLoS ONE. 2013;8:e54019 pubmed publisher
    ..TRY), ENHANCER OF TRY AND CPC 1, 2, 3/CPC-LIKE MYB 3 (ETC1, ETC2, ETC3/CPL3), TRICHOMELESS 1, 2/CPC-LIKE MYB 4 (TCL1, TCL2/CPL4)] and the bHLH transcription factors [GLABRA3 (GL3) and ENHANCER OF GLABRA 3 (EGL3)] are central ..
  8. Shukla A, Cutucache C, Sutton G, Pitner M, Rai K, Rai S, et al. Absence of caveolin-1 leads to delayed development of chronic lymphocytic leukemia in Eμ-TCL1 mouse model. Exp Hematol. 2016;44:30-7.e1 pubmed publisher
    ..Therefore, we decreased the expression of Cav-1 in vivo by breeding Eμ-TCL1 with cav-1 knockout mice...
  9. Ehrlich L, Yang Iott K, Bassing C. Tcrδ translocations that delete the Bcl11b haploinsufficient tumor suppressor gene promote atm-deficient T cell acute lymphoblastic leukemia. Cell Cycle. 2014;13:3076-82 pubmed publisher
    ..While these translocations target and activate the TCL1 oncogene at 14q32 to cause T cell pro-lymphocytic leukemia (T-PLL), the TCRα/δ;14q32 translocations in ATM-..
  10. Khoury J. Blastic Plasmacytoid Dendritic Cell Neoplasm. Curr Hematol Malig Rep. 2018;13:477-483 pubmed publisher a highly sensitive marker for BPDCN and augments diagnostic specificity alongside CD4, CD56, CD123, and TCL1. The gene expression profile of BPDCN is characterized by aberrant NF-kappaB pathway activation, while its genomic ..
  11. Hanna B, Roessner P, Scheffold A, Jebaraj B, Demerdash Y, Oztürk S, et al. PI3Kδ inhibition modulates regulatory and effector T-cell differentiation and function in chronic lymphocytic leukemia. Leukemia. 2018;: pubmed publisher
    ..The role of Tregs in CLL and their modulation by PI3Kδ inhibitors was so far poorly understood. Using the Eµ-TCL1 adoptive transfer model of CLL, we show that disease development induces the accumulation of activated and highly ..
  12. Mizuno S, Hanamura I, Ota A, Karnan S, Narita T, Ri M, et al. Overexpression of salivary-type amylase reduces the sensitivity to bortezomib in multiple myeloma cells. Int J Hematol. 2015;102:569-78 pubmed publisher
    ..These findings provide clues for developing treatment approaches for not only amylase-producing myeloma, but also relapsed and refractory myelomas. ..
  13. Zhang N, Yang L, Luo S, Wang X, Wang W, Cheng Y, et al. Genetic evidence suggests that GIS functions downstream of TCL1 to regulate trichome formation in Arabidopsis. BMC Plant Biol. 2018;18:63 pubmed publisher
    ..STEMS) functions upstream of the MBW activator complex to regulate trichome formation, and that the expression of TCL1 is not regulated by the MBW complex...
  14. Zhang Y, Zhang J, Shao C, Bao Z, Liu G, Bao M. Single-repeat R3 MYB transcription factors from Platanus acerifolia negatively regulate trichome formation in Arabidopsis. Planta. 2019;249:861-877 pubmed publisher
    ..including CAPRICE (CPC), TRIPTYCHON (TRY), ENHANCER OF TRY AND CPC 1, 2 and 3 (ETC1, ETC2 and ETC3), TRICHOMELESS1 (TCL1) and TRICHOMELESS2(TCL2) play important roles in controlling trichome patterning in Arabidopsis...
  15. French S, Shen R, Koh P, Malone C, Mallick P, Teitell M. A modeled hydrophobic domain on the TCL1 oncoprotein mediates association with AKT at the cytoplasmic membrane. Biochemistry. 2002;41:6376-82 pubmed
    ..Induction of AKT serine/threonine kinase activity is augmented by the T-cell leukemia-1 (TCL1) oncoprotein through a physical association requiring the AKT pleckstrin homology domain...
  16. Forte A, Schettino M, Finicelli M, Cipollaro M, Colacurci N, Cobellis L, et al. Expression pattern of stemness-related genes in human endometrial and endometriotic tissues. Mol Med. 2009;15:392-401 pubmed publisher
    ..profiles of a panel of 13 genes (SOX2, SOX15, ERAS, SALL4, OCT4, NANOG, UTF1, DPPA2, BMI1, GDF3, ZFP42, KLF4, TCL1) were analyzed by reverse transcription-polymerase chain reaction in human endometriotic (n = 12) and endometrial ..
  17. Ogasawara M, Liu J, Pelicano H, Hammoudi N, Croce C, Keating M, et al. Alterations of mitochondrial biogenesis in chronic lymphocytic leukemia cells with loss of p53. Mitochondrion. 2016;31:33-39 pubmed publisher
    ..Since p53 affects mitochondrial function and integrity, we examined possible mitochondrial changes in CLL mice with TCL1-Tg/p53-/- and TCL1-Tg/p53+/+ genotypes and in primary leukemia cells from CLL patients with ..
  18. Hayakawa K, Formica A, Brill Dashoff J, Shinton S, Ichikawa D, Zhou Y, et al. Early generated B1 B cells with restricted BCRs become chronic lymphocytic leukemia with continued c-Myc and low Bmf expression. J Exp Med. 2016;213:3007-3024 pubmed
    ..Here, we show that transfer of early generated B1 B cells from E?-TCL1 transgenic mice resulted in chronic lymphocytic leukemia (CLL) with a biased repertoire, including stereotyped BCRs...
  19. Tian H, Wang X, Guo H, Cheng Y, Hou C, Chen J, et al. NTL8 Regulates Trichome Formation in Arabidopsis by Directly Activating R3 MYB Genes TRY and TCL1. Plant Physiol. 2017;174:2363-2375 pubmed publisher
    ..the expression level of the single-repeat R3 MYB genes TRIPTYCHON (TRY) and TRICHOMELESS1 (TCL1) was elevated in the ntl8-1D mutant...
  20. Galvagni F, Lentucci C, Neri F, Dettori D, De Clemente C, Orlandini M, et al. Snai1 promotes ESC exit from the pluripotency by direct repression of self-renewal genes. Stem Cells. 2015;33:742-50 pubmed publisher
    ..Snai1 mediates the repression of pluripotency genes by binding directly to the promoters of Nanog, Nr5a2, Tcl1, c-Kit, and Tcfcp2l1...
  21. Cardinaud B, Moreilhon C, Marcet B, Robbe Sermesant K, Lebrigand K, Mari B, et al. miR-34b/miR-34c: a regulator of TCL1 expression in 11q- chronic lymphocytic leukaemia?. Leukemia. 2009;23:2174-7 pubmed publisher
  22. Schrader A, Crispatzu G, Oberbeck S, Mayer P, Pützer S, von Jan J, et al. Actionable perturbations of damage responses by TCL1/ATM and epigenetic lesions form the basis of T-PLL. Nat Commun. 2018;9:697 pubmed publisher
    ..We formulate a multi-dimensional model of T-PLL pathogenesis centered around a unique combination of TCL1 overexpression with damaging ATM aberrations as initiating core lesions...
  23. Weissferdt A, Rodriguez Canales J, Liu H, Fujimoto J, Wistuba I, Moran C. Primary mediastinal seminomas: a comprehensive immunohistochemical study with a focus on novel markers. Hum Pathol. 2015;46:376-83 pubmed publisher
    ..4 (SALL4), GATA binding protein 3 (GATA-3), sry-related HMG box 2 (SOX2), SOX17, human T cell leukemia/lymphoma 1 (TCL1), glypican 3, melanoma associated antigen C2 (MAGEC2), and paired box gene 8 (Pax8)...
  24. Motiwala T, Kutay H, Zanesi N, Frissora F, Mo X, Muthusamy N, et al. PTPROt-mediated regulation of p53/Foxm1 suppresses leukemic phenotype in a CLL mouse model. Leukemia. 2015;29:1350-9 pubmed publisher
    ..Although lymphocyte development is normal in these mice, crossing them with TCL1 Tg mouse model of CLL results in a survival advantage compared with the TCL1 Tg mice...
  25. Tang C, Chang S, Hashimoto A, Chen Y, Kang C, Mato A, et al. Secretory IgM Exacerbates Tumor Progression by Inducing Accumulations of MDSCs in Mice. Cancer Immunol Res. 2018;6:696-710 pubmed publisher
    ..However, it is not clear whether secretory IgM (sIgM) plays a role in disease progression. We crossed the Eμ-TCL1 mouse model of CLL, in which the expression of human TCL1 oncogene was driven by the V(H) promoter-Ig(H)-Eμ ..
  26. Woo S, Lee H, Oh S, Kim S, Park S, Lee J, et al. Stabilization of HDAC1 via TCL1-pAKT-CHFR axis is a key element for NANOG-mediated multi-resistance and stem-like phenotype in immune-edited tumor cells. Biochem Biophys Res Commun. 2018;503:1812-1818 pubmed publisher
    ..Collectively, our results establish a firm molecular link in immune-edited tumor cells among NANOG, AKT, CHFR, and HDAC1, identifying HDAC1 as a molecular target in controlling NANOGHIGH immune-refractory cancer. ..
  27. Zaborsky N, Gassner F, Höpner J, Schubert M, Hebenstreit D, Stark R, et al. Exome sequencing of the TCL1 mouse model for CLL reveals genetic heterogeneity and dynamics during disease development. Leukemia. 2019;33:957-968 pubmed publisher
    The TCL1 mouse model is widely used to study pathophysiology, clonal evolution, and drug sensitivity or resistance of chronic lymphocytic leukemia (CLL)...
  28. Hanna B, Roessner P, Yazdanparast H, Colomer D, Campo E, Kugler S, et al. Control of chronic lymphocytic leukemia development by clonally-expanded CD8+ T-cells that undergo functional exhaustion in secondary lymphoid tissues. Leukemia. 2019;33:625-637 pubmed publisher
    ..However, the role of T-cells in CLL remains largely controversial. Here, we utilized the Eµ-TCL1 mouse model of CLL as well as blood and lymph node samples of CLL patients to investigate the existence of anti-..
  29. Heinig K, Gätjen M, Grau M, Stache V, Anagnostopoulos I, Gerlach K, et al. Access to follicular dendritic cells is a pivotal step in murine chronic lymphocytic leukemia B-cell activation and proliferation. Cancer Discov. 2014;4:1448-65 pubmed publisher
    ..Using the murine Eμ-Tcl1 CLL model, we demonstrate that CXCR5-controlled access to follicular dendritic cells confers proliferative stimuli ..
  30. Umamaheswaran G, Kadambari D, Kumar A, Revathy M, Anjana R, Adithan C, et al. Polymorphic genetic variations of cytochrome P450 19A1 and T-cell leukemia 1A genes in the Tamil population. Environ Toxicol Pharmacol. 2015;39:102-13 pubmed publisher
    ..Our results emphasize the importance of normative frequency documentation and will offer significant clinical relevance in personalizing AIs therapy. ..
  31. Wu F, Xu W, Li J. [Research Progress in Transgenic Animal Models of Chronic Lymphocytic Leukemia -Review]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2017;25:259-263 pubmed publisher
    ..Among all the models, TCL1 transgenic model is the most commonly used one...
  32. Janovská P, Verner J, Kohoutek J, Bryjova L, Gregorova M, Dzimkova M, et al. Casein Kinase 1 is a Therapeutic Target in Chronic Lymphocytic Leukemia. Blood. 2018;: pubmed publisher
    ..CLL cells and analyzed the therapeutic potential in vivo using two murine model systems based on the Eµ-TCL1-induced leukemia (syngeneic adoptive transfer model and spontaneous disease development), which resemble closely ..
  33. Pekarsky Y, Drusco A, Kumchala P, Croce C, Zanesi N. The long journey of TCL1 transgenic mice: lessons learned in the last 15 years. Gene Expr. 2015;16:129-35 pubmed publisher
    The first transgenic mouse of the TCL1 oncogene was described more than 15 years ago, and since then, the overexpression of the gene in T- and B-cells in vivo has been extensively studied to reveal the molecular details in the ..
  34. Frankel A, Woo J, Ahn C, Foss F, Duvic M, Neville P, et al. Resimmune, an anti-CD3ε recombinant immunotoxin, induces durable remissions in patients with cutaneous T-cell lymphoma. Haematologica. 2015;100:794-800 pubmed publisher
    ..Further studies of Resimmune in patients with low tumor burden, stage IB-IIB cutaneous T-cell lymphoma are warranted. This trial is registered at as #NCT00611208. ..
  35. Bu N, Wu H, Yao J, Zhang J, Gao Y, Guo X. [A clinical analysis of 21 cases of adrenal non-Hodgkin's lymphoma]. Zhonghua Nei Ke Za Zhi. 2015;54:22-6 pubmed
    ..It progressed quickly with poor prognosis. Clinical and imaging features were not specific, so misdiagnosis was very common. Pathology is the diagnostic gold standard. The most common type was diffuse large B cell type. ..
  36. Lee H, Noh K, Lee Y, Song K, Oh S, Kim S, et al. NANOG signaling promotes metastatic capability of immunoedited tumor cells. Clin Exp Metastasis. 2015;32:429-39 pubmed publisher
    ..immunotherapy conferred tumor cells with immune-resistant and stem-like phenotypes by hyper-activating NANOG/TCL1/AKT signaling axis...
  37. Tu J, Tian G, Cheung H, Wei W, Lee T. Gas5 is an essential lncRNA regulator for self-renewal and pluripotency of mouse embryonic stem cells and induced pluripotent stem cells. Stem Cell Res Ther. 2018;9:71 pubmed publisher
    ..Gas5 formed a positive feedback network with a group of key pluripotent modulators (Sox2, Oct4, Nanog, Tcl1, Esrrb, and Tet1) in mESCs...
  38. Leich E, Zamo A, Horn H, Haralambieva E, Puppe B, Gascoyne R, et al. MicroRNA profiles of t(14;18)-negative follicular lymphoma support a late germinal center B-cell phenotype. Blood. 2011;118:5550-8 pubmed publisher
    ..In conclusion, t(14;18)-negative FL have distinct microRNA profiles that are associated with an increased proliferative capacity and a "late" germinal center B-cell phenotype. ..
  39. López Guerra M, Xargay Torrent S, Colomer D. CXCR5-mediated shaping of the lymphoid follicle in chronic lymphocytic leukemia. Cancer Discov. 2014;4:1374-6 pubmed publisher
    Heinig and colleagues, using the Eμ-Tcl1 mouse model of chronic lymphocytic leukemia (CLL), shed light on the trafficking routes of CLL cells into the protective microenvironmental niches in secondary lymphoid organs...
  40. Zaborsky N, Gassner F, Asslaber D, Reinthaler P, Denk U, Flenady S, et al. CD1d expression on chronic lymphocytic leukemia B cells affects disease progression and induces T cell skewing in CD8 positive and CD4CD8 double negative T cells. Oncotarget. 2016;7:49459-49469 pubmed publisher
    ..By using TCL1 mice as a CLL model, we show that TCR-Vβ7+ NK1...
  41. Hiromura M, Okada F, Obata T, Auguin D, Shibata T, Roumestand C, et al. Inhibition of Akt kinase activity by a peptide spanning the betaA strand of the proto-oncogene TCL1. J Biol Chem. 2004;279:53407-18 pubmed
    ..We have demonstrated previously that TCL1 (a proto-oncogene underlying human T cell prolymphocytic leukemia) interacts with Akt and functions as an Akt ..
  42. Trinh D, Shibata K, Hirosawa T, Umezu T, Mizuno M, Kajiyama H, et al. Diagnostic utility of CD117, CD133, SALL4, OCT4, TCL1 and glypican-3 in malignant germ cell tumors of the ovary. J Obstet Gynaecol Res. 2012;38:841-8 pubmed publisher
    ..The aim of this study was to investigate the frequency of CD117, CD133, SALL4, OCT4, TCL1 and glypican-3 marker expression in OMGCTs...
  43. Alhakeem S, McKenna M, Oben K, Noothi S, Rivas J, Hildebrandt G, et al. Chronic Lymphocytic Leukemia-Derived IL-10 Suppresses Antitumor Immunity. J Immunol. 2018;200:4180-4189 pubmed publisher
    ..We used the transgenic Eμ-T cell leukemia oncogene-1 (TCL1) mouse CLL model to study the role of IL-10 in CLL associated immunosuppression...
  44. Shin S, Roh J, Cha H, Choi Y, Kim J, Min S, et al. TCL1 expression predicts overall survival in patients with mantle cell lymphoma. Eur J Haematol. 2015;95:583-94 pubmed publisher
    ..It is difficult to identify indolent MCL cases prospectively. T-cell leukemia/lymphoma protein 1 (TCL1) is expressed by several B-cell lymphomas, including MCL...
  45. Martinez D, Navarro A, Martínez Trillos A, Molina Urra R, González Farre B, Salaverria I, et al. NOTCH1, TP53, and MAP2K1 Mutations in Splenic Diffuse Red Pulp Small B-cell Lymphoma Are Associated With Progressive Disease. Am J Surg Pathol. 2016;40:192-201 pubmed publisher
    ..molecular studies identified complex karyotypes in 2 cases, and IGH rearrangements in 3, with PAX5 and potentially TCL1 as partners in each one of them...
  46. Okihiro A, Hasija R, Fung L, Cameron B, Feldman B, Laxer R, et al. Development of neoplasms in pediatric patients with rheumatic disease exposed to anti-tumor necrosis factor therapies: a single Centre retrospective study. Pediatr Rheumatol Online J. 2018;16:17 pubmed publisher
    ..Long-term screening for rare neoplasms is important as part of the safety monitoring for any pediatric rheumatology patient receiving anti-TNF therapy. ..
  47. Rao S, Durga I, Gopi C, Venkata Tulasivarma C, Kim S, Kim H. The effect of TiO2 nanoflowers as a compact layer for CdS quantum-dot sensitized solar cells with improved performance. Dalton Trans. 2015;44:12852-62 pubmed publisher
    ..Under one sun illumination (AM 1.5 G, 100 mW cm(-2)), the QDSSCs showed PCEs of 2.19 and 2.93% for TCL1 and TCL2 based photoelectrodes, which are higher than the 1.33% value obtained with bare TiO2...
  48. Herman S, Montraveta A, Niemann C, Mora Jensen H, Gulrajani M, Krantz F, et al. The Bruton Tyrosine Kinase (BTK) Inhibitor Acalabrutinib Demonstrates Potent On-Target Effects and Efficacy in Two Mouse Models of Chronic Lymphocytic Leukemia. Clin Cancer Res. 2017;23:2831-2841 pubmed publisher
    ..b>Experimental Design: Two distinct mouse models were used, the TCL1 adoptive transfer model where leukemic cells from Eμ-TCL1 transgenic mice are transplanted into C57BL/6 mice, and ..
  49. Sugimoto K, Shimada A, Wakabayashi M, Sekiguchi Y, Izumi H, Ota Y, et al. T-cell lymphoblastic leukemia/lymphoma with t(7;14)(p15;q32) [TCR?-TCL1A translocation]: a case report and a review of the literature. Int J Clin Exp Pathol. 2014;7:2615-23 pubmed
    ..13). There have been at least 10 reported cases of T-LBL with t(7;14)(p15;q32), including the present case. However, this is the first reported case in which TCR?-TCL1A translocation was confirmed by FISH. ..
  50. Iacovelli S, Hug E, Bennardo S, Duehren von Minden M, Gobessi S, Rinaldi A, et al. Two types of BCR interactions are positively selected during leukemia development in the Eμ-TCL1 transgenic mouse model of CLL. Blood. 2015;125:1578-88 pubmed publisher
    ..of CLL, we evaluated the capacity of different types of antigen/BCR interactions to induce leukemia in the Eμ-TCL1 transgenic mouse model...
  51. Stengel A, Kern W, Zenger M, Perglerová K, Schnittger S, Haferlach T, et al. Genetic characterization of T-PLL reveals two major biologic subgroups and JAK3 mutations as prognostic marker. Genes Chromosomes Cancer. 2016;55:82-94 pubmed publisher
    ..A large subset (86% of patients) showed abnormalities involving the TCRA/D locus activating the proto-oncogenes TCL1 or MTCP1, while the second group was characterized by a high frequency of TP53 mutations (4/7 cases)...
  52. Hanna B, McClanahan F, Yazdanparast H, Zaborsky N, Kalter V, Rößner P, et al. Depletion of CLL-associated patrolling monocytes and macrophages controls disease development and repairs immune dysfunction in vivo. Leukemia. 2016;30:570-9 pubmed publisher
    ..Using the Eμ-TCL1 mouse model, we observed severe skewing of myeloid cell populations with CLL development...
  53. Zhao X, Xu W, Wu J, Zhang D, Abou Shakra A, Di L, et al. Nicotine induced autophagy of Leydig cells rather than apoptosis is the major reason of the decrease of serum testosterone. Int J Biochem Cell Biol. 2018;100:30-41 pubmed publisher
    ..In addition, the methylation level of the promoter region of TCL1 is increased in the nicotine-treated group compared to the control group, consequently decreasing the expression of ..
  54. Hunter J, Butterworth J, Zhao B, Sellier H, Campbell K, Thomas H, et al. The NF-κB subunit c-Rel regulates Bach2 tumour suppressor expression in B-cell lymphoma. Oncogene. 2016;35:3476-84 pubmed publisher
    ..c-Rel loss also led to earlier onset of disease in a separate TCL1-Tg-driven lymphoma model...
  55. Vasyutina E, Boucas J, Bloehdorn J, Aszyk C, Crispatzu G, Stiefelhagen M, et al. The regulatory interaction of EVI1 with the TCL1A oncogene impacts cell survival and clinical outcome in CLL. Leukemia. 2015;29:2003-14 pubmed publisher
    ..Overall, we present regressive EVI1 as a novel regulatory signature in CLL. Through enhanced TCL1A and other EVI1-targeted hallmarks of CLL, this contributes to an aggressive cellular and clinical phenotype. ..
  56. Ruiz Ballesteros E, Mollejo M, Mateo M, Algara P, Martinez P, Piris M. MicroRNA losses in the frequently deleted region of 7q in SMZL. Leukemia. 2007;21:2547-9 pubmed
  57. Gätjen M, Brand F, Grau M, Gerlach K, Kettritz R, Westermann J, et al. Splenic Marginal Zone Granulocytes Acquire an Accentuated Neutrophil B-Cell Helper Phenotype in Chronic Lymphocytic Leukemia. Cancer Res. 2016;76:5253-65 pubmed publisher
    ..In the E?-Tcl1 murine model of CLL, we identified gene expression signatures indicative of a skewed polarization in the phenotype ..
  58. French S, Dawson D, Chen H, Rainey R, Sievers S, Balatoni C, et al. The TCL1 oncoprotein binds the RNase PH domains of the PNPase exoribonuclease without affecting its RNA degrading activity. Cancer Lett. 2007;248:198-210 pubmed
    b>TCL1 is an AKT kinase coactivator that, when dysregulated, initiates mature lymphocyte malignancies in humans and transgenic mice...
  59. Mittal A, Chaturvedi N, Rai K, Gilling Cutucache C, Nordgren T, Moragues M, et al. Chronic lymphocytic leukemia cells in a lymph node microenvironment depict molecular signature associated with an aggressive disease. Mol Med. 2014;20:290-301 pubmed publisher
    ..LN; n = 15) and validated key pathway genes by real-time polymerase chain reaction, immunohistochemistry and/or TCL1 trans-genic mice...
  60. Crawley B, Sulica L. Vocal Fold Paralysis as a Delayed Consequence of Neck and Chest Radiotherapy. Otolaryngol Head Neck Surg. 2015;153:239-43 pubmed publisher
    ..The potential for recovery is low, but injection augmentation can relieve symptoms. Development of contralateral neuropathy and altered tissue response are considerations in treatment. ..
  61. Chen S, Chang B, Chang S, Tong T, Ham S, Sherry B, et al. BTK inhibition results in impaired CXCR4 chemokine receptor surface expression, signaling and function in chronic lymphocytic leukemia. Leukemia. 2016;30:833-43 pubmed publisher
    ..Here, we investigated BTK regulation of leukemic B-cell trafficking in a mouse model of aggressive TCL1 CLL-like disease...
  62. Gutjahr J, Szenes E, Tschech L, Asslaber D, Schlederer M, Roos S, et al. Microenvironment-induced CD44v6 promotes early disease progression in chronic lymphocytic leukemia. Blood. 2018;: pubmed publisher
    ..the in vivo contribution of standard CD44 and its variants to leukemic B-cell homing and proliferation in Tcl1 transgenic mice with a B-cell-specific CD44 deficiency...
  63. Prinz C, Vasyutina E, Lohmann G, Schrader A, Romanski S, Hirschhäuser C, et al. Organometallic nucleosides induce non-classical leukemic cell death that is mitochondrial-ROS dependent and facilitated by TCL1-oncogene burden. Mol Cancer. 2015;14:114 pubmed publisher
    ..The pro-survival oncogene T-cell leukemia 1 (TCL1) is causally linked to the high threshold towards classical apoptosis in CLL...
  64. López C, Bergmann A, Paul U, Murga Penas E, Nagel I, Betts M, et al. Genes encoding members of the JAK-STAT pathway or epigenetic regulators are recurrently mutated in T-cell prolymphocytic leukaemia. Br J Haematol. 2016;173:265-73 pubmed publisher
    ..These findings complement the mutational spectrum of secondary aberrations in T-PLL and underscore the potential therapeutical relevance of epigenetic regulators in T-PLL. ..
  65. Tang C, Zundell J, Ranatunga S, Lin C, Nefedova Y, Del Valle J, et al. Agonist-Mediated Activation of STING Induces Apoptosis in Malignant B Cells. Cancer Res. 2016;76:2137-52 pubmed publisher
    ..In Eμ-TCL1 mice with chronic lymphocytic leukemia, injection of the STING agonist 3'3'-cGAMP induced apoptosis and tumor ..
  66. Khaw S, Min Wen C, Koh C, Lim B, Shyh Chang N. Oocyte Factors Suppress Mitochondrial Polynucleotide Phosphorylase to Remodel the Metabolome and Enhance Reprogramming. Cell Rep. 2015;12:1080-8 pubmed publisher
    ..Here, we show that the oocyte-enriched factors Tcl1 and Tcl1b1 significantly enhance reprogramming efficiency...
  67. Hegebarth D, Buschhaus C, Wu M, Bird D, Jetter R. The composition of surface wax on trichomes of Arabidopsis thaliana differs from wax on other epidermal cells. Plant J. 2016;88:762-774 pubmed publisher
    ..waxes from a mutant lacking trichomes (gl1) were compared to waxes from wild type and a trichome-rich mutant (cpc tcl1 etc1 etc3)...
  68. Zemanova J, Hylse O, Collakova J, Vesely P, Oltova A, Borsky M, et al. Chk1 inhibition significantly potentiates activity of nucleoside analogs in TP53-mutated B-lymphoid cells. Oncotarget. 2016;7:62091-62106 pubmed publisher
    ..Finally, we observed a fludarabine potentiation by SCH900776 in a T-cell leukemia 1 (TCL1)-driven mouse model of CLL...
  69. Magro C, Momtahen S, Nguyen G, Wang X. Histiocytoid Sweet's Syndrome: A localized cutaneous proliferation of macrophages frequently associated with chronic myeloproliferative disease. Eur J Dermatol. 2015;25:335-41 pubmed publisher
    ..Variable positivity for myeloid dendritic cell markers including CD11c, BDCA-3, TCL1 oncogene, MXA and CD123 was observed...
  70. Zheng K, Tian H, Hu Q, Guo H, Yang L, Cai L, et al. Ectopic expression of R3 MYB transcription factor gene OsTCL1 in Arabidopsis, but not rice, affects trichome and root hair formation. Sci Rep. 2016;6:19254 pubmed publisher
    ..protein database using the entire amino acid sequence of Arabidopsis R3 MYB transcription factor TRICHOMELESS1 (TCL1), we found that there are two genes in rice genome encoding R3 MYB transcription factors, namely Oryza sativa ..
  71. Niemann C, Mora Jensen H, Dadashian E, Krantz F, Covey T, Chen S, et al. Combined BTK and PI3Kδ Inhibition with Acalabrutinib and ACP-319 Improves Survival and Tumor Control in CLL Mouse Model. Clin Cancer Res. 2017;23:5814-5823 pubmed publisher
    ..combined with the PI3Kδ inhibitor ACP-319 in vivo We compared single-agent with combination therapy in TCL1-192 cell-injected mice, a model of aggressive CLL...
  72. Herling M, Patel K, Teitell M, Konopleva M, Ravandi F, Kobayashi R, et al. High TCL1 expression and intact T-cell receptor signaling define a hyperproliferative subset of T-cell prolymphocytic leukemia. Blood. 2008;111:328-37 pubmed
    The T-cell leukemia 1 (TCL1) oncoprotein is overexpressed by chromosomal rearrangement in the majority of cases of T-cell prolymphocytic leukemia (T-PLL)...
  73. Pekarsky Y, Balatti V, Palamarchuk A, Rizzotto L, Veneziano D, Nigita G, et al. Dysregulation of a family of short noncoding RNAs, tsRNAs, in human cancer. Proc Natl Acad Sci U S A. 2016;113:5071-6 pubmed publisher
    ..common human leukemia, and transgenic mouse studies indicate that activation of the T-cell leukemia/lymphoma 1 (TCL1) oncogene is a contributing event in the pathogenesis of the aggressive form of this disease...
  74. Roccabianca P, Avallone G, Rodriguez A, Crippa L, Lepri E, Giudice C, et al. Cutaneous Lymphoma at Injection Sites: Pathological, Immunophenotypical, and Molecular Characterization in 17 Cats. Vet Pathol. 2016;53:823-32 pubmed publisher
    ..Persistent inflammation induced by the injection and by reactivation of FeLV expression may have contributed to emergence of CLIS. ..
  75. Ho M, Ingle J, Bongartz T, Kalari K, Goss P, Shepherd L, et al. TCL1A Single-Nucleotide Polymorphisms and Estrogen-Mediated Toll-Like Receptor-MYD88-Dependent Nuclear Factor-?B Activation: Single-Nucleotide Polymorphism- and Selective Estrogen Receptor Modulator-Dependent Modification of Inflammation and Immune R. Mol Pharmacol. 2017;92:175-184 pubmed publisher
    ..These observations greatly expand the range of pathways influenced by TCL1A genotype and raise the possibility that this estrogen- and SNP-dependent regulation might be altered pharmacologically by SERMs. ..
  76. French S, Malone C, Shen R, Renard M, Henson S, Miner M, et al. Sp1 transactivation of the TCL1 oncogene. J Biol Chem. 2003;278:948-55 pubmed
    Cis-regions and trans-factors controlling TCL1 oncogene expression are not known. We identified the functional TCL1 promoter by mapping four transcriptional start sites 24-30 bp downstream of a TATA box...
  77. Herling M, Patel K, Hsi E, Chang K, Rassidakis G, Ford R, et al. TCL1 in B-cell tumors retains its normal b-cell pattern of regulation and is a marker of differentiation stage. Am J Surg Pathol. 2007;31:1123-9 pubmed
    The high expression of the T-cell oncogene TCL1 in B-cell tumors and the emergence of B-cell lymphomas in TCL1-transgenic mice suggest a pathogenetic role for this kinase coregulator in B-cell malignancies...
  78. Cui B, Ghia E, Chen L, Rassenti L, Deboever C, Widhopf G, et al. High-level ROR1 associates with accelerated disease progression in chronic lymphocytic leukemia. Blood. 2016;128:2931-2940 pubmed publisher
    ..ROR1 is a receptor for Wnt5a that may complex with TCL1, a coactivator of AKT that is able to promote development of CLL...
  79. Ichikawa K, Noguchi M, Imai H, Sekiguchi Y, Wakabayashi M, Sawada T, et al. A case of T cell prolymphocytic leukemia involving blast transformation. Int J Hematol. 2011;93:667-672 pubmed publisher
    ..It is known that indolent T-PLL can become aggressive. Therefore, similar transformations may occur in other aggressive T-PLL cases, particularly those involving trisomy 8 and TCL1a. ..
  80. Palmer V, Nganga V, Rothermund M, Perry G, Swanson P. Cd1d regulates B cell development but not B cell accumulation and IL10 production in mice with pathologic CD5(+) B cell expansion. BMC Immunol. 2015;16:66 pubmed publisher
    ..Interestingly, in the CLL-prone Eμ-TCL1 model, loss of CD1d expression suppressed spontaneous IgG (but not IgM) production, whereas in the dnRAG1xEμ-..
  81. Yigit B, Halibozek P, Chen S, O Keeffe M, Arnason J, Avigan D, et al. A combination of an anti-SLAMF6 antibody and ibrutinib efficiently abrogates expansion of chronic lymphocytic leukemia cells. Oncotarget. 2016;7:26346-60 pubmed publisher
    ..upon transplantation of a well-defined aggressive murine B220+CD5+ Chronic Lymphocytic Leukemia (CLL) cell clone, TCL1-192, into SCID mice one injection of a monoclonal antibody directed against SLAMF6 (αSlamf6) abrogates tumor ..
  82. Carter M, Cox K, Blakemore S, Turaj A, Oldham R, Dahal L, et al. PI3K? inhibition elicits anti-leukemic effects through Bim-dependent apoptosis. Leukemia. 2017;31:1423-1433 pubmed publisher
    ..In vitro, PI3K?i-induced substantive apoptosis and disrupted microenvironment-derived signaling in murine (E?-Tcl1) and human (CLL) leukemia cells...
  83. Mazzoccoli L, Robaina M, Apa A, Bonamino M, Pinto L, Queiroga E, et al. MiR-29 silencing modulates the expression of target genes related to proliferation, apoptosis and methylation in Burkitt lymphoma cells. J Cancer Res Clin Oncol. 2018;144:483-497 pubmed publisher
    ..miR-29a/b/c were transfected to the BL cell lines BL41 and Raji, and evaluated for DNMT3B, MCL1, BIM, CDK6, AKT and TCL1 protein expression as well as for MCL-1 and CDK6 mRNA expression...
  84. Bianco M, Gasparri A, Generoso L, Assi E, Colombo B, Scarfo L, et al. Inhibition of chronic lymphocytic leukemia progression by full-length chromogranin A and its N-terminal fragment in mouse models. Oncotarget. 2016;7:41725-41736 pubmed publisher
    ..3 ?g, i.v., or 1.5 ?g/mouse, i.p.) can reduce the BM/blood ratio of leukemic cells in E?-TCL1 mice, a transgenic model, and decrease BM, lung and kidney infiltration in Rag2-/-?c-/- mice engrafted with human ..
  85. Dürr C, Hanna B, Schulz A, Lucas F, Zucknick M, Benner A, et al. Tumor necrosis factor receptor signaling is a driver of chronic lymphocytic leukemia that can be therapeutically targeted by the flavonoid wogonin. Haematologica. 2018;103:688-697 pubmed publisher
    ..The therapeutic effects of wogonin were analyzed in mice after adoptive transfer of -T-cell leukemia 1 (TCL1) leukemic cells. Wogonin treatment prevented leukemia development when given early after transplantation...
  86. Ho M, Lummertz da Rocha E, Zhang C, Ingle J, Goss P, Shepherd L, et al. TCL1A, a Novel Transcription Factor and a Coregulator of Nuclear Factor ?B p65: Single Nucleotide Polymorphism and Estrogen Dependence. J Pharmacol Exp Ther. 2018;365:700-710 pubmed publisher
    ..Integrated RNA-seq and ChIP-seq results suggest that TCL1A also acts as a transcriptional coregulator with NF-?B p65, an important immune system transcription factor. ..
  87. Johnston H, Carter M, Cox K, Dunscombe M, Manousopoulou A, Townsend P, et al. Integrated Cellular and Plasma Proteomics of Contrasting B-cell Cancers Reveals Common, Unique and Systemic Signatures. Mol Cell Proteomics. 2017;16:386-406 pubmed publisher
    ..The B-cell-specific overexpression of the myc and TCL1 oncogenes in mice induce spontaneous malignancies modeling BL and CLL, respectively...
  88. Gorini F, Azzimonti L, Delfanti G, Scarfo L, Scielzo C, Bertilaccio M, et al. Invariant NKT cells contribute to chronic lymphocytic leukemia surveillance and prognosis. Blood. 2017;129:3440-3451 pubmed publisher
    ..We investigated the impact of iNKT cells in the natural history of the disease in the E?-Tcl1 (Tcl1) CLL mouse model and 68 CLL patients...
  89. Cramer S, Saha A, Liu J, Tadi S, Tiziani S, Yan W, et al. Systemic depletion of L-cyst(e)ine with cyst(e)inase increases reactive oxygen species and suppresses tumor growth. Nat Med. 2017;23:120-127 pubmed publisher
    ..reduced tumor growth in both prostate and breast cancer xenografts and doubled the median survival time of TCL1-Tg:p53-/- mice, which develop disease resembling human chronic lymphocytic leukemia...
  90. Pekarsky Y, Zanesi N, Aqeilan R, Croce C. Tcl1 as a model for lymphomagenesis. Hematol Oncol Clin North Am. 2004;18:863-79, ix pubmed
    ..In this article we discuss molecular mechanisms leading to the pathogenesis of two major types of mature leukemias and lymphomas: mature T-cell leukemia and chronic lymphocytic leukemia. ..
  91. Lemal R, Bard Sorel S, Montrieul L, Bay J, Ravinet A, Ledoux Pilon A, et al. TCL1 expression patterns in Waldenström macroglobulinemia. Mod Pathol. 2016;29:83-8 pubmed publisher
    The oncogenic role of TCL1 in chronic lymphocytic leukemia is well established in transgenic mice...
  92. Gaudio E, Spizzo R, Paduano F, Luo Z, Efanov A, Palamarchuk A, et al. Tcl1 interacts with Atm and enhances NF-?B activation in hematologic malignancies. Blood. 2012;119:180-7 pubmed publisher
    The T-cell leukemia/lymphoma 1 (TCL1) oncogene is a target of chromosomal translocations and inversions at 14q31.2, and its rearrangement in T cells causes T-cell prolymphocytic leukemias...